Coming This
Summer!

A Phase 2/3 clinical trial in recurrent pericarditis of KPL-387, an investigational monoclonal antibody IL-1 receptor antagonist in a liquid formulation, with a target profile of once-monthly subcutaneous dosing.

For more information please visit clinicaltrials.gov

Every
second
counts!™

Vanessa

Living with
Recurrent Pericarditis

It’s  . Today, right at this moment, we’re hard at work for patients like Vanessa who have a critical therapeutic need. We approach everything we do with a sense of urgency because, for them, we understand the clock is ticking—and that every second makes a difference.

 

Learn More

RECENT INVESTOR NEWS

Kiniksa Pharmaceuticals Presents at 42nd Annual J.P. Morgan Healthcare Conference

View webcast of Chief Executive Officer and Chairman Sanj K. Patel’s presentation on Kiniksa’s portfolio of immune-modulating assets.

WATCH HERE

CEO Story

Fighting for a brighter future, one second at a time.

Sanj K. Patel, CEO and Chairman of the Board of Kiniksa Pharmaceuticals, brings more than 30 years of experience in the biopharmaceutical industry to build a company that puts patients first.
Watch Video

Patient Stories

Serving those who
don’t have time to wait.

Living with a debilitating disease brings questions that go far beyond the symptoms—there’s the fear and frustration of not knowing when, or if, there will ever be an answer. That’s why we’re relentless about making every moment matter at Kiniksa: because every second brings us closer to creating a better future for patients. Hear stories from the people who live with the uncertainty of these diseases every day.

hear
Jill's story

Watch Video
Living with
Recurrent Pericarditis

hear
Nadine’s story

Watch Video
Living with
Recurrent Pericarditis

hear
Vanessa's story

Watch Video
Living with
Recurrent Pericarditis

Connect with us on social media for up-to-date news and discoveries.

 

Follow us